The Gilead Foundation announced a USD 12 million investment in 33 community‑based organizations spanning 14 states and...
Eli Lilly and Company (NYSE: LLY) announced that China’s Center for Drug Evaluation (CDE) under...
Pyrotech (Beijing) Biotechnology Co., Ltd. (“Pyrotech Therapeutics”) announced that its internally developed small‑molecule innate immune...
Beijing Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced that China’s National Medical Products Administration (NMPA) has...
Rallybio Corporation (NASDAQ: RLYB) and Candid Therapeutics, Inc. announced a definitive merger agreement whereby Rallybio will...
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China’s National Medical Products Administration (NMPA) has...
China Medical System Holdings Limited (CMS, HKG: 0867) announced clinical study approval from China’s National Medical...
Edding Genor Group Holdings Limited (HKG: 6998) announced a supplemental agreement and termination agreement with Napeptide...
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that Xuanyuening (bireociclib), a Category 1 CDK2/4/6 inhibitor developed...
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the completion of a financing round raising RMB 1.277 billion...
Bio-Thera Solutions Ltd (SHA: 688177) announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA)...
Star Sports Medicine Co., Ltd., a China‑based sports medical device manufacturer, submitted a prospectus to...
Kexing Biopharm Co., Ltd. (SHA: 688136) announced clinical trial approval from China’s National Medical Products Administration...
Johnson & Johnson (J&J, NYSE: JNJ) announced that its investigational drug nipocalimab has received Fast Track...
Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly...
Insilico Medicine (HKG: 3696), a generative AI‑driven biotech, announced the pilot launch of its Automated Partnering...
Teva Pharmaceuticals (NYSE: TEVA) and Blackstone Life Sciences (BXLS) announced a $400 million strategic funding agreement over...
Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176), a urogenital cancer specialist, announced marketing approval from China’s...
Antengene Corp., Ltd (HKG: 6996) announced a licensing agreement with UCB (EBR: UCB), granting the Belgium‑based biopharma...
Sino Biopharmaceutical Ltd (HKG: 1177) announced a licensing agreement with Sanofi SA (NASDAQ: SNY) for rovadicitinib, a...